Cargando…
Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147485/ https://www.ncbi.nlm.nih.gov/pubmed/35631359 http://dx.doi.org/10.3390/ph15050533 |
_version_ | 1784716818830589952 |
---|---|
author | Alonso-García, Miriam Sánchez-Gastaldo, Amparo Muñoz-Fuentes, Miguel A. Molina-Pinelo, Sonia Boyero, Laura Benedetti, Johana Cristina Bernabé-Caro, Reyes |
author_facet | Alonso-García, Miriam Sánchez-Gastaldo, Amparo Muñoz-Fuentes, Miguel A. Molina-Pinelo, Sonia Boyero, Laura Benedetti, Johana Cristina Bernabé-Caro, Reyes |
author_sort | Alonso-García, Miriam |
collection | PubMed |
description | Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared in clinical trials. This retrospective, single-centre study was performed from June 2015 to December 2020 and included a cohort of 158 previously treated patients with stage IV or recurrent NSCLC who received PD-1 (nivolumab) (n = 89) or PD-L1 (atezolizumab) (n = 69) inhibitors at the Virgen del Rocío Hospital in Seville. The objective response rate (ORR) was 22.5% in the nivolumab group and 14.5% in the atezolizumab group (p = 0.140). Multivariate analysis did not show significant differences between the two groups for PFS and OS (PFS hazard ratio (HR): 0.80, 95% confidence interval (CI): 0.55–1.17, p = 0.260; OS HR: 0.79, 95% CI: 0.52–1.21, p = 0.281). Adverse events of all grades occurred in 68 patients in the nivolumab group (76.4%) and in 34 patients in the atezolizumab group (49.3%) (p < 0.001). Atezolizumab and nivolumab did not show statistically significant differences in survival outcomes in patients with NSCLC, even when stratified by histological subtype (squamous versus nonsquamous). However, the safety analysis suggested a more favourable toxicity profile for atezolizumab. |
format | Online Article Text |
id | pubmed-9147485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91474852022-05-29 Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer Alonso-García, Miriam Sánchez-Gastaldo, Amparo Muñoz-Fuentes, Miguel A. Molina-Pinelo, Sonia Boyero, Laura Benedetti, Johana Cristina Bernabé-Caro, Reyes Pharmaceuticals (Basel) Article Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared in clinical trials. This retrospective, single-centre study was performed from June 2015 to December 2020 and included a cohort of 158 previously treated patients with stage IV or recurrent NSCLC who received PD-1 (nivolumab) (n = 89) or PD-L1 (atezolizumab) (n = 69) inhibitors at the Virgen del Rocío Hospital in Seville. The objective response rate (ORR) was 22.5% in the nivolumab group and 14.5% in the atezolizumab group (p = 0.140). Multivariate analysis did not show significant differences between the two groups for PFS and OS (PFS hazard ratio (HR): 0.80, 95% confidence interval (CI): 0.55–1.17, p = 0.260; OS HR: 0.79, 95% CI: 0.52–1.21, p = 0.281). Adverse events of all grades occurred in 68 patients in the nivolumab group (76.4%) and in 34 patients in the atezolizumab group (49.3%) (p < 0.001). Atezolizumab and nivolumab did not show statistically significant differences in survival outcomes in patients with NSCLC, even when stratified by histological subtype (squamous versus nonsquamous). However, the safety analysis suggested a more favourable toxicity profile for atezolizumab. MDPI 2022-04-25 /pmc/articles/PMC9147485/ /pubmed/35631359 http://dx.doi.org/10.3390/ph15050533 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Alonso-García, Miriam Sánchez-Gastaldo, Amparo Muñoz-Fuentes, Miguel A. Molina-Pinelo, Sonia Boyero, Laura Benedetti, Johana Cristina Bernabé-Caro, Reyes Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer |
title | Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer |
title_full | Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer |
title_fullStr | Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer |
title_full_unstemmed | Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer |
title_short | Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer |
title_sort | real-world analysis of nivolumab and atezolizumab efficacy in previously treated patients with advanced non-small cell lung cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147485/ https://www.ncbi.nlm.nih.gov/pubmed/35631359 http://dx.doi.org/10.3390/ph15050533 |
work_keys_str_mv | AT alonsogarciamiriam realworldanalysisofnivolumabandatezolizumabefficacyinpreviouslytreatedpatientswithadvancednonsmallcelllungcancer AT sanchezgastaldoamparo realworldanalysisofnivolumabandatezolizumabefficacyinpreviouslytreatedpatientswithadvancednonsmallcelllungcancer AT munozfuentesmiguela realworldanalysisofnivolumabandatezolizumabefficacyinpreviouslytreatedpatientswithadvancednonsmallcelllungcancer AT molinapinelosonia realworldanalysisofnivolumabandatezolizumabefficacyinpreviouslytreatedpatientswithadvancednonsmallcelllungcancer AT boyerolaura realworldanalysisofnivolumabandatezolizumabefficacyinpreviouslytreatedpatientswithadvancednonsmallcelllungcancer AT benedettijohanacristina realworldanalysisofnivolumabandatezolizumabefficacyinpreviouslytreatedpatientswithadvancednonsmallcelllungcancer AT bernabecaroreyes realworldanalysisofnivolumabandatezolizumabefficacyinpreviouslytreatedpatientswithadvancednonsmallcelllungcancer |